| Heading: |
Cancer: Drugs |
| Question ID: |
1758079 |
| UIN: |
HL4314 |
| House: |
Lords |
| Date tabled: |
2025-01-22 |
| Asking Member ID: |
4286 |
| Asking Member display name: |
Lord Mendelsohn
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Lord Mendelsohn
|
| Member interest: |
false |
| Question text: |
To ask His Majesty's Government what steps they are taking steps to prioritise the use of cost and clinically effective cancer medicines that result in fewer patient visits to hospital. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-01-29 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
347 |
| Answering Member display name: |
Baroness Merron
|
| Answering Member handle: |
|
| Answering Member Twitter reference: |
Baroness Merron
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The National Institute for Health and Care Excellence (NICE) makes recommendations on whether all new medicines, including cancer medicines, should be routinely funded by the National Health Service based on an assessment of their costs and benefits. The ... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |